203 related articles for article (PubMed ID: 35075066)
1. Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review.
Sasi S; Mohamed M; Chitrambika P; Yassin M
Acta Biomed; 2022 Jan; 92(6):e2021437. PubMed ID: 35075066
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency.
Hochman MJ; Smith BD; Karantanos T; Braunstein EM; Gojo I; Jain T; Streiff MB; Moliterno AR; DeZern AE
Int J Hematol; 2023 Mar; 117(3):456-462. PubMed ID: 36181657
[TBL] [Abstract][Full Text] [Related]
3. Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
Swaminathan M; Patel KP; Huynh-Lu J; Tang G; Zuo Z; Miranda R; Verstovsek S
Acta Haematol; 2019; 141(1):23-27. PubMed ID: 30463063
[TBL] [Abstract][Full Text] [Related]
4. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase targeted treatment of chronic myelogenous leukemia and other myeloproliferative neoplasms.
Bisen A; Claxton DF
Adv Exp Med Biol; 2013; 779():179-96. PubMed ID: 23288640
[TBL] [Abstract][Full Text] [Related]
6. Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Yue Y; Wei W; Guo Y; Wang F; Dong W; Liu Y; Lin Y; Cao Y; Gu W
Am J Case Rep; 2020 Oct; 21():e925151. PubMed ID: 33021971
[TBL] [Abstract][Full Text] [Related]
7. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
Ryu J; Chu D; Park B; Kim M; Cho YU; Hwang SH; Jang S; Seo EJ; Lee JH; Park CJ
Lab Med; 2022 Nov; 53(6):e140-e144. PubMed ID: 35243502
[TBL] [Abstract][Full Text] [Related]
8. Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.
Pandey R; Kapur R
Mol Cancer; 2015 Jun; 14():118. PubMed ID: 26062813
[TBL] [Abstract][Full Text] [Related]
9. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
Czader M; Orazi A
Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
[TBL] [Abstract][Full Text] [Related]
10. Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis.
Thomas K; Rao R; G V C; Rai S; Rao A R S; Basavaraju Vatsala K
F1000Res; 2023; 12():503. PubMed ID: 38434629
[No Abstract] [Full Text] [Related]
11. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
12.
Tarantini F; Cumbo C; Zagaria A; Parciante E; Anelli L; Coccaro N; Tota G; Minervini CF; Redavid I; Rossi AR; Conserva MR; Specchia G; Musto P; Albano F
Hematology; 2022 Dec; 27(1):842-846. PubMed ID: 35938951
[TBL] [Abstract][Full Text] [Related]
13. Muscle-specific kinase antibody associated myasthenia gravis after bone marrow transplantation.
Heidarzadeh Z; Mousavi SA; Ostovan VR; Nafissi S
Neuromuscul Disord; 2014 Feb; 24(2):148-50. PubMed ID: 24314584
[TBL] [Abstract][Full Text] [Related]
14. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
15. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
Shaikh AB; Aribandi A; Gupta A; Subramanian SK; Goyal M
Indian J Pathol Microbiol; 2021; 64(4):820-823. PubMed ID: 34673614
[TBL] [Abstract][Full Text] [Related]
16. Sequential Development of JAK2V617F Mutation and BCR-ABL1 Fusion in Individual Patients With Myeloproliferative Neoplasms.
Zhao Y; Reddi D; McCracken J; Iranzad N; Rehder C; Neff J; Wang E
Arch Pathol Lab Med; 2022 Jun; 146(6):710-717. PubMed ID: 34506622
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
19. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.
Pizzi M; Croci GA; Ruggeri M; Tabano S; Dei Tos AP; Sabattini E; Gianelli U
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830822
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
Yan J; Ding YW; Wang PY; Wu YP; Zhang HC; Liu LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]